奥雷拉布鲁丁尼,莱纳利多米德加上辛蒂利马布的安全性和临床结果用于复发性/耐药性扩散性大B细胞淋巴瘤
Lingling Wang1, Yongfen Huang1, Dan Xu2
1Department of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
这项研究评估了奥雷拉布鲁替尼,莱纳利多米德和辛蒂利马布用于复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL). 该组合显示出有希望的疗效,58.8%的客观反应率和可管理的安全性在中国患者.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性/耐药性扩散性大B细胞淋巴瘤 (R/R DLBCL) 呈现出显著的未满足需求.
- 新型治疗组合对于改善R/R DLBCL的结果至关重要.
研究的目的:
- 评估ORELABRUTINIB,Lenalidomide和Sintilimab在R/RDLBCL患者中的安全性和临床疗效.
- 评估治疗应答率,生存结果和与这种联合治疗相关的不良事件.
主要方法:
- 一组34名患有R/RDLBCL的患者接受了奥雷拉布鲁替尼,列纳利多米德和辛蒂利马布.
- 治疗涉及每种药物的特定的每日和周期性剂量方案.
- 在研究期间,监测了安全性,疗效和生存终点.
主要成果:
- 一年无进展生存率 (PFS) 和整体生存率 (OS) 分别为41.9%和77.8%.
- 客观反应率 (ORR) 为58.8%,完全缓解率 (CR) 为38.2%.
- 与治疗相关的不良事件 (TRAE) 是常见的 (82%),在20.6%的患者中发生了3级或更高的TRAE;中性质衰竭和血小板衰竭最常见.
结论:
- 奥雷拉布鲁丁尼,莱纳利多米德和辛蒂利马布的组合在中国的R/R DLBCL患者中显示出有前途的疗效.
- 该治疗方案表现出可管理的安全性,支持其作为治疗选择的潜力.
更多相关视频
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Clinical Trials: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
